Ken Griffin increased his stake in Johnson & Johnson by 146% in Q1 2026, bringing his total holdings to nearly 2 million shares. The article highlights J&J as an ideal stock for risk-averse investors due to its diversified portfolio of 28+ billion-dollar products, strong revenue growth in pharmaceuticals and medtech following the Kenvue spinoff, and its status as a Dividend King with 50+ consecutive years of dividend increases and a 2% yield.

The article compares Church & Dwight and Kimberly-Clark as investment options in the consumer goods sector. Church & Dwight operates a lean portfolio of power brands with a strong balance sheet (0.6x debt-to-equity), while Kimberly-Clark is a larger global player undergoing transformation with higher leverage (4.9x debt-to-equity). The author recommends Church & Dwight for investors seeking a balance of growth and dividend income, citing its stronger financial position and focused strategy, despite Kimberly-Clark's larger scale and higher dividend yield.

Kimberly-Clark is outperforming the S&P 500 and Nasdaq in 2026 with a 4.5% dividend yield and 54 consecutive years of dividend increases. The company trades at a discount valuation (15.2x 2026 earnings vs. 21.9x historical median) and is acquiring Kenvue to diversify revenue streams and unlock $2.1 billion in annual synergies. However, risks include execution challenges from the acquisition and potential dividend sustainability concerns.

Colgate-Palmolive has surged 20.4% year-to-date and stands out as a Dividend King with 63 consecutive years of dividend increases. Despite industry headwinds from inflation and consumer resistance to price increases, the company has demonstrated resilience through its elite brand portfolio, efficient operations, and strong geographic diversification. Trading at 25x forward earnings with a 2.2% dividend yield, the stock is positioned to continue outperforming broader market indexes in the second half of 2026.

The article recommends three healthcare stocks for long-term buy-and-hold portfolios: Johnson & Johnson, Abbott Laboratories, and UnitedHealth Group. All three are praised for their stable dividends, strong cash flows, economic moats, and ability to weather economic downturns. Johnson & Johnson and Abbott are Dividend Kings with 64 and 54 consecutive years of dividend increases respectively, while UnitedHealth Group benefits from its dual-engine model combining insurance and healthcare delivery.

The article recommends three dividend stocks for long-term 10-year investors: Clorox (strengthened by its Purell acquisition and offering a 5% yield), Brown-Forman (with 42 consecutive years of dividend increases and a 3.6% yield despite current market softness), and Kimberly-Clark (undergoing major transformation with trusted brands and 50+ years of dividend growth). All three are positioned as overlooked opportunities for patient investors seeking steady compounding returns.

In an uncertain market marked by tariff-driven inflation and low consumer sentiment, the article recommends three consumer staples companies as stable investments for a $1,000 allocation: Church & Dwight for its volume-driven growth, Keurig Dr Pepper for its high-growth energy drink portfolio, and Kenvue for its strong beauty and health brands ahead of its merger with Kimberly-Clark.

The article compares Kimberly-Clark and Clorox as investment options for 2026. Both companies face challenges including high debt loads, customer concentration risk (Walmart accounts for 16-27% of sales), and intense competition. Kimberly-Clark is undergoing significant restructuring with a potential $48 billion merger with Kenvue and selling its international tissue business, while Clorox is recovering from a 2023 cyberattack and pandemic-era slowdown. The author recommends Clorox as the safer choice due to its stronger brand positioning, though acknowledges Kimberly-Clark offers higher upside potential despite greater integration risks.

Three consumer goods dividend stocks are positioned for growth: Hershey benefits from a 74% drop in cocoa prices enabling margin expansion; General Mills offers a 7% yield amid transformation and cost structure improvements; Kimberly-Clark is acquiring Kenvue to create a scaled personal-care platform with strong brands and long-term dividend durability.

Kimberly-Clark is recommended as a defensive dividend stock for potential market downturns due to its essential consumer staples products, 54-year dividend increase streak, and attractive 5.2% yield. Despite a 30% stock price decline from its June high due to the $48.7 billion Kenvue acquisition financing concerns, the stock's low P/E ratio of 15 and strong free cash flow support suggest limited downside risk.

Hedge fund billionaire Daniel Loeb reduced his stake in Kenvue Inc. by 64% in Q4 2025, cutting holdings from 9.0 million to 3.25 million shares. The consumer health company, which includes brands like Tylenol and Listerine, is undergoing a restructuring that will reduce workforce by 3.5% with $250 million in charges expected in 2026. Kenvue's acquisition by Kimberly-Clark at $48.7 billion enterprise value is expected to close in H2 2026 pending regulatory approval.

The article recommends three dividend stocks for investors seeking income: PepsiCo, which is showing signs of recovery after underperformance; Kenvue, a spinoff from Johnson & Johnson offering reliable recurring income with an upcoming merger; and Procter & Gamble, a consumer staples giant with 70 consecutive years of dividend increases.